Chronic Inducible Urticaria is a group of chronic urticarias characterized by the appearance of recurrent wheals, recurrent angioedema, or both, as a response to specific triggers.
The market size of Chronic Inducible Urticaria is anticipated to rise at a significant CAGR during the study period of 2017–2030. Among all 7MM, the United States accounted for the largest Chronic Inducible Urticaria market size.
Among EU5 countries, Germany had the largest market size of Chronic Inducible Urticaria, with USD 172 million in 2017, while Spain had the smallest Chronic Inducible Urticaria market size with USD 104.5 million in 2017.
Chronic Inducible Urticaria market drivers
- Need for curative therapy
- Increasing awareness
- Rising prevalence
Chronic Inducible Urticaria market barriers
- Need for biomarkers
- Complex pathophysiology
- Patient adherence
- Need for Chronic Inducible Urticaria specific population studies
The therapeutic goal of Chronic Inducible Urticaria management primarily focuses on achieving complete symptom control by trigger avoidance and desensitization, blocking the effects of mast cell mediators (non- sedating, second-generation antihistamines), and prevention of mast cell degranulation. Currently, there is no approved therapy for Chronic Inducible Urticaria treatment apart from symptomatic management. The pipeline scenario does not show a particularly close picture with only one major player making significant inroads in the largely untapped market. AK002 (Antolimab), being developed by Allakos Pharma, is the only drug with the potential to enter the arena during the forecast period and has completed Phase II trials.
1 Key Insights
2 Executive Summary of Chronic Inducible Urticaria
3 SWOT Analysis for Chronic Inducible Urticaria
4 Chronic Inducible Urticaria Epidemiology Overview at a Glance
4.1 Patient Share (%) Distribution of Chronic Inducible Urticaria in 2017
4.2 Patient Share (%) Distribution of Chronic Inducible Urticaria in 2030
5 Chronic Inducible Urticaria Market Overview at a Glance
5.1 Market Share (%) Distribution of Chronic Inducible Urticaria in 2017
5.2 Market Share (%) Distribution of Chronic Inducible Urticaria in 2030
6 Disease Background and Overview
6.1 Introduction
6.2 Types
6.3 Pathophysiology
6.4 Clinical features
6.5 Diagnosis
6.6 Clinical manifestation
7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Total Prevalent Population of CIndU in 7MM
7.3 Assumptions and Rationale: 7MM
8 Country Wise-Epidemiology of Chronic Inducible Urticaria
8.1 The United States
8.1.1 Diagnosed Prevalent cases of CU in the United States
8.1.2 Diagnosed Prevalent cases of CIndU in the United States
8.1.3 Prevalence of Chronic Inducible Urticaria by Types in the United States
8.2 EU5
8.2.1 Germany
8.2.2 France
8.2.3 Italy
8.2.4 Spain
8.2.5 The United Kingdom
8.3 Japan
8.3.1 Diagnosed Prevalent cases of CU in Japan
8.3.2 Diagnosed Prevalent cases of CIndU in Japan
8.3.3 Prevalence of Chronic Inducible Urticaria by Types in Japan
9 Treatment and Management
9.1 Guidelines
10 Case Study
10.1 Severe cold urticaria including anaphylaxis
10.2 Severe symptomatic dermographism (urticaria factitia)
11 Patient Journey
12 Unmet Needs
13 Emerging Therapies
13.1 AK002: Allakos Inc.
13.1.1 Product Description
13.1.2 Clinical Development
13.1.3 Safety and Efficacy
14 Other Promising Therapies
14.1 CDX-0159: Celldex Therapeutics
14.1.1 Product Description
14.1.2 Clinical Development
14.1.3 Safety and Efficacy
15 Chronic Inducible Urticaria: Seven Major Market Analysis
15.1 Key Findings
15.2 Market Size of Chronic Inducible Urticaria (CIndU) in 7MM
16 Market Outlook by Country
16.1 Assumption and Rationale
16.2 United States
16.2.1 Total Market size of Chronic Inducible Urticaria (CIndU)
16.2.2 Chronic Inducible Urticaria Market Size by Therapies
16.3 Germany
16.3.1 Total Market size of Chronic Inducible Urticaria (CIndU)
16.3.2 Chronic Inducible Urticaria Market Size by Therapies
16.4 France
16.4.1 Total Market size of Chronic Inducible Urticaria (CIndU)
16.4.2 Chronic Inducible Urticaria Market Size by Therapies
16.5 Italy
16.5.1 Total Market size of Chronic Inducible Urticaria (CIndU)
16.5.2 Chronic Inducible Urticaria Market Size by Therapies
16.6 Spain
16.6.1 Total Market size of Chronic Inducible Urticaria (CIndU)
16.6.2 Chronic Inducible Urticaria Market Size by Therapies
16.7 UK
16.7.1 Total Market size of Chronic Inducible Urticaria (CIndU)
16.7.2 Chronic Inducible Urticaria Market Size by Therapies
16.8 Japan
16.8.1 Total Market size of Chronic Inducible Urticaria (CIndU)
16.8.2 Chronic Inducible Urticaria Market Size by Therapies
17 Market Drivers
18 Market Barriers
19 Appendix
19.1 Report Methodology
20 DelveInsight Capabilities
21 Disclaimer
22 About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/